UK dermatitis patients get early access to Sanofi's dupilumab

14 March 2017

French pharma major Sanofi (Euronext: SAN) has received a positive scientific opinion under the UK’s Early Access to Medicines Scheme (EAMS) for the investigational dermatitis medicine dupilumab.

The aim of the scheme is to provide early availability of innovative new unlicensed medicines to UK patients that have a high degree of unmet clinical need.

Dupilumab will now be available to eligible adult patients throughout the UK who suffer from severe atopic dermatitis (AD) and have failed to respond to, or are otherwise ineligible for other currently approved therapies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK